hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06305780 id: Pro00112597 id: OTA-21-015G type: OTHER domain: NIH Grant to RTI; RTI subcontracting with DCRI briefTitle: RECOVER-AUTONOMIC Platform Protocol overallStatus: ENROLLING_BY_INVITATION date: 2024-03-11 date: 2025-12 date: 2026-03 date: 2024-03-12 date: 2024-04-08 name: Kanecia Obie Zimmerman class: OTHER briefSummary: This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.
nctId: NCT06305767 id: V940-005 id: V940-005 type: OTHER domain: Merck id: U1111-1292-1952 type: OTHER domain: WHO id: 2023-505658-17 type: OTHER domain: EU CT briefTitle: A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005) overallStatus: RECRUITING date: 2024-03-28 date: 2026-10-08 date: 2031-04-08 date: 2024-03-12 date: 2024-04-25 name: Merck Sharp & Dohme LLC class: INDUSTRY name: ModernaTX, Inc. briefSummary: The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection. The primary study hypothesis is that V940 in combination with pembrolizumab results in a superior disease-free survival (DFS) as assessed by the investigator compared to pembrolizumab alone in participants with high-risk MIUC after radical resection. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: Pembrolizumab name: V940 name: Placebo measure: Disease Free Survival (DFS) measure: Overall Survival (OS) measure: Distant Metastasis-Free Survival (DMFS) measure: Number of Participants Who Experience an Adverse Event (AE) measure: Number of Participants Who Discontinue Study Treatment Due to an AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0102) status: RECRUITING city: Orlando state: Florida zip: 32804 country: United States name: Study Coordinator role: CONTACT phone: 205-520-6512 lat: 28.53834 lon: -81.37924 facility: One Clinical Research ( Site 1807) status: RECRUITING city: Nedlands state: Western Australia zip: 6009 country: Australia name: Study Coordinator role: CONTACT phone: +61862799466 lat: -31.98184 lon: 115.8073 facility: Centre Hospitalier de l'Université de Montréal ( Site 0005) status: RECRUITING city: Montréal state: Quebec zip: H2X 3E4 country: Canada name: Study Coordinator role: CONTACT phone: 5148908000 lat: 45.50884 lon: -73.58781 facility: Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 status: RECRUITING city: Quebec City state: Quebec zip: G1J 1Z4 country: Canada name: Study Coordinator role: CONTACT phone: 4185254444 lat: 46.81228 lon: -71.21454 facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0801) status: RECRUITING city: Bydgoszcz state: Kujawsko-pomorskie zip: 85-796 country: Poland name: Study Coordinator role: CONTACT phone: 48501446778 lat: 53.1235 lon: 18.00762 facility: HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1003) status: RECRUITING city: Pozuelo de Alarcon state: Madrid zip: 28223 country: Spain name: Study Coordinator role: CONTACT phone: +34914521987 lat: 40.43293 lon: -3.81338 hasResults: False
nctId: NCT06305754 id: 2870-009 id: 2023-504910-31 type: REGISTRY domain: EU CT id: U1111-1288-3804 type: OTHER domain: UTN id: MK-2870-009 type: OTHER domain: Merck briefTitle: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) overallStatus: NOT_YET_RECRUITING date: 2024-06-03 date: 2028-09-12 date: 2030-06-14 date: 2024-03-12 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY briefSummary: The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS). conditions: Non-small Cell Lung Cancer (NSCLC) studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Unblinded Open-label whoMasked: OUTCOMES_ASSESSOR count: 520 type: ESTIMATED name: Sacituzumab tirumotecan name: Pemetrexed name: Carboplatin name: Antihistamine name: H2 Receptor Antagonist name: Acetaminophen (or equivalent) name: Dexamethasone (or equivalent) measure: Progression-Free Survival (PFS) measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Duration of Response (DOR) measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score measure: Change From Baseline in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30 measure: Change from Baseline in the Cough (Item 31) Score, on the EORTC Lung-Cancer specific Quality of Life Questionnaire (QLQ-LC13) measure: Change from Baseline in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13 measure: Time to Deterioration (TTD) in Global Health Status/Quality of Life (Items 29 and 30) Combined Score, on the EORTC QLQ-C30 measure: TTD in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30 measure: TTD in the Cough (Item 31) Score, on the EORTC QLQ-LC13 measure: TTD in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13 measure: Number of Participants Who Experience One or More Adverse Events (AEs) measure: Number of Participants Who Discontinue Study Treatment Due to an AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305741 id: 24-060 briefTitle: A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers overallStatus: RECRUITING date: 2024-03-05 date: 2026-03 date: 2026-03 date: 2024-03-12 date: 2024-03-12 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: The purpose of this study is to find out if an anxiety treatment program is practical and effective for Latino older adults with cancer (OACs) and their caregivers. conditions: Cancer Patients conditions: Care Givers studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Managing Anxiety from Cancer (MAC) measure: percentage of participants to complete all study procedures sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (All Protocol Activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (All Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (All Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center (All protocol activities) status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (All Protocol Activities) status: RECRUITING city: Rockville Centre state: New York zip: 11553 country: United States name: Kelly McConnell, PhD role: CONTACT phone: 646-888-0026 lat: 40.65871 lon: -73.64124 hasResults: False
nctId: NCT06305728 id: 23-367 briefTitle: A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC) overallStatus: RECRUITING date: 2024-03-04 date: 2030-03-04 date: 2030-03-04 date: 2024-03-12 date: 2024-03-12 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts:
* The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan) conditions: Pancreatic Cyst studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: 89Zr-DFO-HuMab-5B1 immunoPET name: HP MRI name: Blood assay measure: Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (Limited protocol activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center (All protocol activites) status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Kevin Soares, MD role: CONTACT phone: 212-639-3195 lat: 40.71427 lon: -74.00597 facility: Weill Cornell Medical Center (Specimen Analysis Only) status: NOT_YET_RECRUITING city: New York state: New York zip: 10065 country: United States name: David Lyden, MD role: CONTACT phone: 212-746-6565 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activites) status: RECRUITING city: Rockville Centre state: New York zip: 11553 country: United States name: Kevin Soares, PhD role: CONTACT phone: 212-639-3195 lat: 40.65871 lon: -73.64124 hasResults: False
nctId: NCT06305715 id: IIT-THOMPSON-RADIANCE-LUNG-X briefTitle: Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-06-15 date: 2028-06-15 date: 2024-03-12 date: 2024-03-12 name: Medical College of Wisconsin class: OTHER briefSummary: This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI). conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: Radiation Therapy name: Targeted TKI therapy measure: Progression Free Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Froedtert Hospital & the Medical College of Wisconsin city: Milwaukee state: Wisconsin zip: 53226 country: United States name: Jonathan Thompson, MD, MS role: CONTACT phone: 414-805-4600 email: jrthomps@mcw.edu lat: 43.0389 lon: -87.90647 hasResults: False
nctId: NCT06305702 id: LZRXN-001 briefTitle: Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer overallStatus: COMPLETED date: 2022-07-01 date: 2023-12-31 date: 2024-01-31 date: 2024-03-12 date: 2024-03-12 name: Liaoning Tumor Hospital & Institute class: OTHER briefSummary: A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy. conditions: HER2-positive Metastatic Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 500 type: ACTUAL name: inetetamab measure: Progression Free Survival(PFS) measure: objective response rate (ORR) measure: Adverse events (AEs) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Liaoning Cancer Hospital &Institue city: Shenyang country: China lat: 41.79222 lon: 123.43278 hasResults: False
nctId: NCT06305676 id: MCC-23073 briefTitle: Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC) acronym: BASH OPC overallStatus: RECRUITING date: 2024-01-22 date: 2029-01 date: 2029-01 date: 2024-03-12 date: 2024-03-13 name: H. Lee Moffitt Cancer Center and Research Institute class: OTHER name: National Institutes of Health (NIH) briefSummary: Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh). conditions: Oropharyngeal Cancer conditions: HPV-Related Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: combined HPV 16 DNA and host gene methylation oral biomarker panel measure: Diagnostic Sensitivity measure: Diagnostic Specificity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Moffitt Cancer Center status: RECRUITING city: Tampa state: Florida zip: 33612 country: United States name: Kimberly Isaacs-Soriano role: CONTACT phone: 813-745-6992 email: kimberly.Isaacs-Soriano@moffitt.org name: Anna Giuliano, PhD role: PRINCIPAL_INVESTIGATOR name: Antonio Amelio, PhD role: PRINCIPAL_INVESTIGATOR name: Jimmy Caudell, MD, PhD role: SUB_INVESTIGATOR name: Christine Chung, MD role: SUB_INVESTIGATOR name: Bruce Wenig, MD role: SUB_INVESTIGATOR lat: 27.94752 lon: -82.45843 facility: University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Jose P. Zevallos, MD, PhD role: CONTACT email: zevallosjp@upmc.edu name: Robert Ferris, PhD role: CONTACT email: ferrrl@UPMC.EDU lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06305663 id: 921 briefTitle: A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children overallStatus: NOT_YET_RECRUITING date: 2024-03-29 date: 2027-01-31 date: 2027-01-31 date: 2024-03-12 date: 2024-03-12 name: Bausch & Lomb Incorporated class: INDUSTRY briefSummary: A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children conditions: Myopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The identity of the study eye will be masked to subjects, assessors, and other masked personnel while masking is maintained.. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 418 type: ESTIMATED name: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic) name: CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens measure: Mean change from baseline in axial length. measure: Mean change from baseline in cycloplegic SERE. sex: ALL minimumAge: 8 Years maximumAge: 12 Years stdAges: CHILD facility: Site 105 city: Beijing state: Beijing zip: 100044 country: China lat: 39.9075 lon: 116.39723 facility: Site 107 city: Dongcheng state: Beijing zip: 100730 country: China facility: Site 109 city: Xiamen state: Fujian zip: 361004 country: China lat: 24.47979 lon: 118.08187 facility: Site 111 city: Haikou state: Hainan zip: 570311 country: China lat: 20.04583 lon: 110.34167 facility: Site 110 city: Wuhan state: Hubei zip: 430012 country: China lat: 30.58333 lon: 114.26667 facility: Site 102 city: Shanghai state: Shanghai zip: 200433 country: China lat: 31.22222 lon: 121.45806 facility: Site 106 city: Taiyuan state: Shanxi zip: 030072 country: China lat: 37.86944 lon: 112.56028 facility: Site 108 city: Shenzhen state: Shenzhen zip: 518040 country: China lat: 22.54554 lon: 114.0683 facility: Site 103 city: Chengdu state: Sichaun Province zip: 610044 country: China lat: 30.66667 lon: 104.06667 facility: Site 104 city: Nankai state: Tianjin zip: 300392 country: China facility: Site 101 city: Wenzhou state: Zhejiang zip: 325027 country: China lat: 27.99942 lon: 120.66682 hasResults: False
nctId: NCT06305650 id: WK2024001 briefTitle: Probiotic Influence on Obesity-Related Lipidemia overallStatus: RECRUITING date: 2024-03-20 date: 2024-06-20 date: 2024-07-30 date: 2024-03-12 date: 2024-04-09 name: Wecare Probiotics Co., Ltd. class: INDUSTRY briefSummary: This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults. Specifically, it will assess the probiotic's impact on body composition metrics such as BMI, body fat percentage, WHR, and BMR. The inclusion criteria for participants are a BMI of ≥28 kg/m\^2, targeting individuals who stand to benefit significantly from metabolic and body composition improvements. conditions: Overweight or Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Double（Participant,Investigator） whoMasked: PARTICIPANT count: 72 type: ESTIMATED name: Probiotic measure: Effect on body mass index (BMI) values. sex: ALL minimumAge: 19 Years maximumAge: 45 Years stdAges: ADULT facility: Henan University of Science and Technology status: RECRUITING city: Luoyang state: Henan zip: 471000 country: China name: Ying Wu, Dr. role: CONTACT phone: +86 18639283502 email: wuying2000@126.com lat: 34.68361 lon: 112.45361 hasResults: False
nctId: NCT06305637 id: KTCS-2302 briefTitle: A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. overallStatus: COMPLETED date: 2023-12-04 date: 2024-02-10 date: 2024-02-10 date: 2024-03-12 date: 2024-03-12 name: Taro Pharmaceuticals USA class: INDUSTRY briefSummary: To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor. conditions: Tinea Versicolor studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 430 type: ACTUAL name: Ketoconazole Shampoo, 2% name: Ketoconazole Shampoo, 2% (Reference Standard) name: Placebo measure: To demonstrate the therapeutic equivalence and safety of the Investigational Product sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taro city: Hawthorne state: New York zip: 10532 country: United States lat: 41.10732 lon: -73.79597 hasResults: False